Low-dose 5-Aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients

Journal of Clinical Oncology

Volumn 18, Issue 5, 2000, Pages 956-962

  Wijermans, P ^a   Lubbert M ^a   Verhoef, G ^a   Bosly, A ^a   Ravoet, C ^a   Andre, M ^a   Ferrant, A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; CYTARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL TRIAL; FEMALE; GERIATRIC PATIENT; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17444452612     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.5.956     Document Type: Article

References (33)

1. Greenberg P, Cox C, LeBeau M, et al: International scoring system for evaluating prognosis in myelodysplastic syndrome. Blood 89:2079-2088, 1997
2. Jones PA, Laird PW: Cancer epigenetics comes of age. Nat Genet 21:163-167, 1999 (review)
3. Herman JG, Jen J, Merlo A, et al: Hypermethylation-associated inactivation indicates a suppressor role for p15INK4B1. Cancer Res 56:722-727, 1996
4. Issa JP, Baylin SB, Herman JG: DNA methylation changes in hematologic malignancies: Biologic and clinical implications. Leukemia 11:S7-S11, 1997 (suppl 1)
5. Jones PA, Taylor SM: Cellular differentiation, cytidine analogues and DNA methylation. Cell 20:85-93, 1980
6. Szyf M: DNA methylation patterns: An additional level of information? Biochem Cell Biol 69:764-767, 1991
7. Lübbert M, Brugger W, Mertelsmann R, et al: Developmental regulation of myeloid gene expression and demethylation during ex vivo culture of peripheral blood progenitor cells. Blood 87:447-455, 1996
8. Pinto A, Attadia V, Fusco A, et al: 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemia. Blood 64:922-929, 1984
9. Koshy H, Molokie R, Dom L, et al: Augmentation of fetal hemoglobin (HbF) levels by low dose short duration 5-aza-2′-deoxycytidine (decitabine) administration in sickle cell anemia patients who had no HbF elevation following hydroxyurea therapy. Blood 92:31b, 1998 (suppl 1, abstr 3105)
10. Richel DJ, Colly LP, Kluin-Nelemans JC, et al: The antileukemic activity of 5-aza-2′-deoxycytidine in patients with relapsed and resistant leukemia. Eur J Haematol 40:199-204, 1988
11. Willemze R, Suciu S, Archimbaud E, et al: A randomized phase II study on the effects of 5-aza-2′-deoxycytidine combined with either amsacrine or idarubicine in patients with relapsed acute leukemia: An EORTC Leukemia Cooperative Group phase II study. Leukemia 11:24-27, 1997 (suppl 1)
12. Kantarjian HM, O'Brien SM, Estey E, et al: Decitabine studies in chronic and acute myelogenous leukemia. Leukemia 11:35-36, 1997 (suppl 1)
13. Silverman LR, Holland JF, Weinberg RS, et al: Effect of treatment with 5-azacytidine on the in vitro and in vivo haematopoiesis in patients with myelodysplastic syndromes. Leukemia 7:21-29, 1993 (suppl 1)
14. Zagonel V, Lo Re G, Marotta G, et al: 5-Aza-2′-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndrome. Leukemia 7:30-35, 1993 (suppl 1)
15. Wijermans PW, Krulder JWM, Huijgens PC, et al: Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:1-5, 1997
16. Gehan AG: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
17. Wijermans PW, Lübbert M, Verhoef G: DNA methylating therapy in MDS: The experience with 5-aza-2′-deoxycytidine, decitabine. Blood 94:306a, 1999 (suppl 1, abstr 1368)
18. Daskalakis M, Nguyen TT, Wijermans PW, et al: Reduction of p15 hypermethylation in bone marrow cells from patients with MDS following treatment with a methyltransferase inhibitor (decitabine). Blood 92:715a, 1998 (suppl 1, abstr 2937)
19. Cheson BD, Simon R: Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndrome: A review of 20 years' experience. Semin Oncol 14:126-133, 1987
20. Miller KB, Kyungmann K, Morrison FS, et al: The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: A phase III intergroup study. Ann Hematol 65:162-168, 1992
21. Gerhartz HH, Marcus R, Delmer A, et al: A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony stimulating factor (rhGM-CSF) in myelodysplastic syndrome (MDS) with a high risk of developing leukemia. Leukemia 8:16-23, 1994
22. Appelbaum FR, Anderson J: Bone marrow transplantation for myelodysplasia in adults and children: When and who. Leuk Res 22:35-40, 1998 (suppl 1)
23. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem-cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998
24. de Witte T, van Biezen A, Hermans J, et al: Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Blood 90:3853-3857, 1997
25. Beran M, Kantarjian H: Topotecan in the treatment of hematologic malignancies. Semin Hematol 35:26-31, 1998 (suppl 4)
26. Beran M, Kantarjian H, Keating M: Results of combination chemotherapy with topotecan and high-dose cytosine arabinoside (Ara-C) in previously untreated patients with high-risk myelodysplastic syndrome and chromic myelomonocytic leukemia. Blood 90:583a, 1997 (suppl 1, abstr 2593)
27. Kizaki M, Koeffler HP: Differentiation-inducing agents in the treatment of myelodysplastic syndromes. Semin Oncol 19:95-105, 1992
28. List AF, Brasfield F, Heaton R, et al: Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90:3364-3369, 1997
29. Bowen DT, Denzlinger C, Brugger W, et al: Poor response rate to a continuous schedule of amifostine therapy for low/intermediate-risk myelodysplastic patients. Br J Haematol 103:785-787, 1998
30. Hellstrom-Lindberg E: Efficacy of erythropoietin in myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 89:67-71, 1995
31. Negrin RS, Stein R, Vardiman J, et al: Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 82:737-743, 1993
32. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al: Treatment of anemia in myelodysplastic syndrome with granulocyte colony-stimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow up of 71 patients. Blood 92:68-75, 1998
33. Miller AM, Noyes WE, Taetle R, et al: Limited erythropoietic response to combined treatment with recombinant interleukin 3 and erythropoietin in myelodysplastic syndrome. Leuk Res 23:77-84, 1999